The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
You guys haven’t a clue down11.5% today tRML isn’t going
Nowhere
Derrrrr!!! Quotes,, I’m topping up ,,,
Cheap..
Good price to enter,,
Well get over it , yr all in La LA land
Yr all going to loose yr money ,, and don’t say
I TOLD. YOU. SO
DooooMeD. Company
DOOOOOMED. sHARE PRICE
Dream on mugs
A strange week, I’ve topped up between 11.89 - 12.8. All my buys reported as a sells apart from my last one today. For the first time it was NT to sell for me. Now can get both 11.28 sell vs 11.89 buy. I thought it would be a lot more active now given that it’s trading under cash in bank, guess it’s a waitIng game for news now.
Looks like a buy to me.
Ok, they are playing the delayed trade game again, I’m assuming that 12.8p 100k shares is a buy as that’s what I was quoted at the time, I’m still getting 12.38p sell v 13.7p buy.
Odd now it’s NT to buy down to £500 then Getting quote for 13.7p to buy. Still 12.38p to sell
12.8p to buy, 12.38p to sell. Can currently easily buy and sell decent volumes.
I have this share at 13 p close from google what is the real price ??
Not many sellers today.
when the blood is flowing and it is bleeding now :-)
Took a loss and sold mate, it’s on free fall due to the seller behind, as you can see 500k delayed sell popping up, low volume, so not many buyers to soak up the sells, and no1 knows when they are gonna finish selling, I can see it keep sliding until they finished selling
Fingers crossed for a pump at some point, a crumb of comfort knowing there is someone still willing to pick the large sells up though.
Flakey, you forgot to add, never buy when there is a crazy seller behind
40 down to 13.5p ,, most probably go lower only supported by cash in bank
I’ve taken loss.. it’s a punt big punt,,
It’s DOOOOOOOOMED
Aarrgh, note to self Never buy when on holiday Never buy when under the influence Always do research Shine a bloody light.
Someone picking up 100000 a time.
Some idiot gone crazy and selling everything up, nonstop drop
Picked up some more at 12.5p
Can't be many seller's around at this level Shirley!
I don’t know what’s going on, I pulled a quote up to sell earlier just for my own reference and had a quote at 13.2p, we had no trades then a smaller sell goes through at 12p, now it’s quoting 11.45p to sell. Is it That there are no orders on the order book? Or a few sell orders on the books at any price that need clearing? Or bringing it down to fill some bigger buy orders? Either way it’s still not churning much volume. It’s only had under £100k in trades below 20p, and around £200k in trades since it was 38p, and now it’s 1/3rd of that price, wiping ~£30m off the Mcap. can there be much stock available around at these prices?
Took a punt here yesterday @13p, would like to think it a good one!
It seems sellers done and buyers back with 100k buys
Novel Therapeutics for Immune-Mediated Diseases
Utilizing our proprietary technology, Realm is developing novel prescription therapeutics with the potential to be first in class immunomodulatory treatments. Our initial target indications are in dermatology: Atopic Dermatitis, Acne Vulgaris and Psoriasis. We have demonstrated that our technology has broad-spectrum immunomodulatory properties and believe it has potential application in many other immune-mediated diseases with significant unmet medical needs.
PR022 for Atopic Dermatitis
PR022 is a proprietary, non-alcohol based, topical gel formulation of high concentration of hypochlorous acid (HOCl), offering a differentiated mechanism of action for the treatment of Atopic Dermatitis.
In pre‑clinical models of Atopic Dermatitis, the Company has demonstrated that PR022 is associated with a statistically significant therapeutic effect, including down modulation of key cytokines IL-4, IL-13 and TARC, as well as cytokines associated with itch, including IL-31 and TSLP. Importantly, these results were demonstrated without the typical immunosuppressive impact of steroids, the current standard of care, suggesting an advantageous safety profile for PR022.
PR022 is currently being studied in a Phase 2 clinical trial. The study is being conducted in the United States and is a randomized, double-blind, vehicle-controlled, multicenter, parallel-group trial to assess the safety and efficacy of PR022 topical gel in approximately 120 adults with mild-to-moderate Atopic Dermatitis. Based on outcomes of this study, the Company intends to conduct a Phase 2b study to include adolescent patients.
Atopic Dermatitis, a serious form of eczema, is a chronic, relapsing, inflammatory disease characterized by itchy, inflamed skin, which poses a significant burden on patients’ quality of life and on the overall health care system. It is most commonly first diagnosed in childhood. Patients with Atopic Dermatitis have impaired function of their skin barrier, which, combined with skin damage as a result of the intense itching and scratching associated with the disease, puts them at risk for secondary infections due to colonization with pathogenic bacteria (particularly Staphylococcus aureus) and changes in the skin microbiome.
Atopic Dermatitis affects an estimated 20 million people in the U.S., including up to 20% of children and up to 3% of adults, and prevalence continues to increase. The Company believes that peak year sales for PR022 could potentially reach $1.0 billion in the U.S. alone, based on market analysis.
RLM023 for Acne
RLM023 is a topical formulation of HOCl that is optimized for Acne. We believe that an HOCl based formulation may offer a promising treatment for Acne due to its anti-inflammatory and anti-microbial properties. In in vitro and in vivo pre-clinical studies, HOCl demonstrated a reduction in the expression of pro-inflammatory cytokines such as TNF-α, IL 1β, IF
As of 30th June - $23.7m / 1.27 = £18.6m / 116.5m = 16p / share. Minus what they have spent, in the meantime. I’m Looking for information on their existing “short term investments” but can’t find much. Anything interesting there?
One third, but the point is well made. I'm in - oversold and should rise based on fundamentals. Any good news will see this price multiply.
Got around 30k at 13p, should double up within a week, sp now one fourth of day before yesterday